[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Investigation Report on China's Iohexol Market 2021-2025

July 2021 | 50 pages | ID: IA9FEA3827DFEN
China Research and Intelligence Co., Ltd.

US$ 2,600.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Iohexol is a non-ionic X-ray contrast agent. Iohexol injection is suitable for intravascular and intracavitary injections in adults and children. In clinical angiography (cerebrovascular angiography, coronary angiography, peripheral and visceral angiography, ventricle angiography), CT-enhanced imaging of the head and body , Intravenous urography (IVP), arthrography, endoscopic retrograde cholangiopancreatography (ERCP), percutaneous transhepatic cholangiography (PTC), hernia or fistula angiography, gastrointestinal angiography, 'T 'Pipeline radiography and so on. Iohexol was developed by Nycomed and was approved to enter the Chinese market in 1997. Since then, some generic drugs have also been listed in the Chinese market. According to CRI’s market research, there are several suppliers in the Chinese Iohexol market by 2020, of which Yangtze River Pharmaceutical Group Co., Ltd. accounts for the most market share.

According to CRI’s market research, the sales value of Iohexol in the Chinese market increased year by year from 2016 to 2019. In 2020, due to the impact of COVID-19 on the hospital's overall diagnosis and treatment services, its sales value of Iohexol in the Chinese market decreased to CNY691 million, a year-on-year decrease of 13.53%. The CAGR of Iohexol sales value in the Chinese market from 2016 to 2020 is 0.45%.

CRI expects that with the relief of COVID-19, the sales of Iohexol in the Chinese market will have a restorative growth from 2021 to 2025. With the popularization of medical services in China and the advancement of medical technology, the demand for iodine and a non-ionic X-ray contrast agent in Chinese medical industry has gradually expanded, and sales value are expected to continue to grow from 2021 to 2025.

Topics Covered:
  • The impact of COVID-19 on China's Iohexol market
  • Sales value of China's Iohexol 2016-2020
  • Competitive landscape of China's Iohexol market
  • Prices of Iohexol in China
  • Prices of Iohexol in China by regions and manufacturers
  • Analysis on factors affecting the development of China's Iohexol market
  • Prospect of China's Iohexol market from 2021 to 2025
1 RELEVANT CONCEPTS OF IOHEXOL

1.1 Indications for Iohexol
1.2 Development of Iohexol in China
1.3 Governmental Approval of Iohexol in China
1.4 The Impact of COVID-19 on Iohexol Sales in China

2 SALES OF IOHEXOL IN CHINA, 2016-2020

2.1 Sales Value of Iohexol
  2.1.1 Overall Sales Value
  2.1.2 Sales Value by Region
2.2 Sales Volume of Iohexol
  2.2.1 Overall Sales Volume
  2.2.2 Sales Volume by Region
2.3 Sales of Iohexol by Dosage Form in China, 2016-2020
  2.3.1 Injection
  2.3.2 Analysis of Other Dosage Form

3 ANALYSIS OF MAJOR IOHEXOL MANUFACTURERS IN CHINA IN 2020

3.1 Analysis of Market Share of Major Iohexol Manufacturers
  3.1.1 Investigation on Market Share by Sales Value
  3.1.2 Investigation on Market Share by Sales volume
3.2 Yangtze River Pharmaceutical Group Co., Ltd.
  3.2.1 Enterprise Profile
  3.2.2 Sales of Ousu (Yangtze River Pharmaceutical Group Co., Ltd. ’s Iohexol) in China
3.3 General Electric Pharmaceuticals (Shanghai) Co., Ltd.
  3.3.1 Enterprise Profile
  3.3.2 Sales of Ounaipaike (General Electric Pharmaceuticals (Shanghai) Co., Ltd.’s Iohexol) in China
3.4 Beijing Beilu Pharmaceutical Co., Ltd.
  3.4.1 Enterprise Profile
  3.4.2 Sales of Shuangbei (Beijing Beilu Pharmaceutical Co., Ltd.’s Iohexol) in China
3.5 Hunan Hansen Pharmaceutical Co., Ltd.
  3.5.1 Enterprise Profile
  3.5.2 Sales of Dianke (Hunan Hansen Pharmaceutical Co., Ltd.’s Iohexol) in China
3.6 Hunan Jinjian Pharmaceutical Co., Ltd.
  3.6.1 Enterprise Profile
  3.6.2 Sales of Shukeming (Hunan Jinjian Pharmaceutical Co., Ltd.’s Iohexol) in China

4 PRICES OF IOHEXOL FOR DIFFERENT MANUFACTURERS IN CHINA, 2020-2021

4.1 Yangtze River Pharmaceutical Group Co., Ltd. (Ousu)
4.2 General Electric Pharmaceuticals (Shanghai) Co., Ltd. (Ounaipaike)
4.3 Beijing Beilu Pharmaceutical Co., Ltd. (Shuangbei)
4.4 Hunan Hansen Pharmaceutical Co., Ltd. (Dianke)
4.5 Hunan Jinjian Pharmaceutical Co., Ltd. (Shukeming)

5 PROSPECT OF CHINESE IOHEXOL MARKET, 2021-2025

5.1 Influential Factors of Chinese Iohexol Market Development
  5.1.1 The Impact of COVID-19 on Chinese Iohexol Market
  5.1.2 Market Drivers and Opportunities
  5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend

LIST OF CHARTS

Chart Patent Information About Iohexol Injection Registration in China
Chart Sales Value of Iohexol Injection over the World
Chart Sales Value of Iohexol Injection in China, 2016-2020
Chart Sales Value of Iohexol Injection in China by Region, 2016-2020
Chart Sales Volume of Iohexol Injection in China, 2016-2020
Chart Sales Volume of Iohexol Injection in China by Region, 2016-2020
Chart Market Share by Sales Value of Top Iohexol Injection Manufacturers in China, 2016-2020
Chart Sales Value and Volume of Ousu in China, 2016-2020
Chart Sales Value and Volume of Ounaipaike in China, 2016-2020
Chart Sales Value and Volume of Shuangbei in China, 2016-2020
Chart Sales Value and Volume of Dianke in China, 2016-2020
Chart Sales Value and Volume of Shukeming in China, 2016-2020
Chart Referential Prices of Ousu in China by Region, 2020-2021
Chart Referential Prices of Ounaipaike in China by Region, 2020-2021
Chart Referential Prices of Shuangbei in China by Region, 2020-2021
Chart Referential Prices of Dianke in China by Region, 2020-2021
Chart Referential Prices of Shukeming in China by Region, 2020-2021
Chart Forecast on Sales Value of Iohexol Injection in China, 2021-2025
Chart Forecast on Sales Volume of Iohexol Injection in China, 2021-2025


More Publications